Competitive Clinical Research Grant
Eli Lilly’s grant funds independent clinical research on lebrikizumab and mirkizumab in dermatology and gastroenterology, focusing on investigator-led studies addressing specific scientific questions.
Funder: Eli Lilly and Company
Due Dates: February 15, 2026: Efficacy of Lebrikizumab in fibrosing skin conditions | February 15, 2026: Lebrikizumab and post-inflammatory dyspigmentation in atopic dermatitis | June 15, 2026: Real-world effectiveness of mirkizumab in IBD (Canada)
Funding Amounts: Funding varies by RFP and project scope; support may include financial grants and/or study drug provision.
Summary: Supports independent, investigator-initiated clinical research aligned with Lilly’s posted RFPs in dermatology and gastroenterology.
Key Information: Applicants must submit a full proposal using Lilly’s forms by the specified RFP deadline.
Description
The Competitive Clinical Research Grant from Eli Lilly and Company provides funding and/or study drug supply for external, investigator-initiated studies in areas of Lilly’s scientific interest. Each grant cycle is driven by specific, publicly posted Requests for Proposals (RFPs) that outline research priorities, such as the efficacy of lebrikizumab in fibrosing skin conditions, the impact of lebrikizumab on post-inflammatory dyspigmentation in atopic dermatitis, and real-world effectiveness of mirkizumab in IBD (Canada). Approved projects are the full responsibility of the grantee, including study design, conduct, and regulatory sponsorship. Proposals are reviewed by global committees of Lilly medical and scientific staff, with external expert input as needed.
